Tocagen’s (NASDAQ:TOCA) Phase 3 Toca 5 clinical trial, evaluating Toca 511 and Toca FC, in patients with recurrent high grade glioma, undergoing resection, missed the primary endpoint of overall survival, compared with standard of care.
In addition, all secondary endpoints showed no meaningful difference between the arms of the trial.
Shares of Tocagen were quoted at 92 cents, down $3.26, or 78%, in heavy turnover at midday on Sept. 12.
“While the Toca 5 trial results are disappointing, we will be conducting a thorough analysis of the data, including molecular analyses and pre-planned subgroups,” Marty Duvall, CEO, said in a statement. “In addition, we will be conducting an operational review.”